AstraZeneca PLC [NASDAQ: AZN] traded at a high on 01/25/21, posting a 1.43 gain after which it closed the day’ session at $54.01. The company report on January 25, 2021 that CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia.
Superior safety on key secondary endpoint of atrial fibrillation.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib.
The results of the trading session contributed to over 13734106 shares changing hands. Over the past one week, the price volatility of AstraZeneca PLC stands at 1.26% while the volatility over the past one month is 1.41%.
The market cap for AZN stock reached $139.06 billion, with 2.62 billion shares outstanding and 2.60 billion shares in the current float. Compared to the average trading volume of 10.40M shares, AZN reached a trading volume of 13734106 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AstraZeneca PLC [AZN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $62.35 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 15, 2021. The new note on the price target was released on December 07, 2020, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 0.90, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.38. The Price to Book ratio for the last quarter was 11.62, with the Price to Cash per share for the same quarter was set at 3.28.
How has AZN stock performed recently?
AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.20. With this latest performance, AZN shares gained by 10.84% in over the last four-week period, additionally sinking by -3.21% over the last 6 months – not to mention a rise of 9.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 66.46, with the RSI for the last a single of trading hit 76.34, and the three-weeks RSI is set at 59.95 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 52.35, while it was recorded at 52.92 for the last single week of trading, and 53.56 for the last 200 days.
AstraZeneca PLC [AZN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +11.51 and a Gross Margin at +72.35. AstraZeneca PLC’s Net Margin is presently recorded at +5.47.
Return on Total Capital for AZN is now 8.66, given the latest momentum, and Return on Invested Capital for the company is 4.59. Return on Equity for this stock inclined to 10.62, with Return on Assets sitting at 2.23. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 138.85. Additionally, AZN Total Debt to Total Capital is recorded at 58.13, with Total Debt to Total Assets ending up at 29.70. Long-Term Debt to Equity for the company is recorded at 123.54, with the Long-Term Debt to Total Capital now at 51.72.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $14,822 per employee. Receivables Turnover for the company is 4.55 with a Total Asset Turnover recorded at a value of 0.41.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.
Earnings analysis for AstraZeneca PLC [AZN]
With the latest financial reports released by the company, AstraZeneca PLC posted 0.45/share EPS, while the average EPS was predicted by analysts to be reported at 0.59/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 19.40%.
Insider trade positions for AstraZeneca PLC [AZN]
There are presently around $22,048 million, or 16.50% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 52,093,683, which is approximately -4.493% of the company’s market cap and around 0.50% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 51,498,061 shares of the stock with an approximate value of $2.78 billion in AZN stocks shares; and FMR LLC, currently with $2.4 billion in AZN stock with ownership of nearly -7.035% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 374 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 17,414,915 shares. Additionally, 273 investors decreased positions by around 37,308,112 shares, while 122 investors held positions by with 353,492,760 shares. The mentioned changes placed institutional holdings at 408,215,787 shares, according to the latest SEC report filing. AZN stock had 113 new institutional investments in for a total of 3,292,284 shares, while 65 institutional investors sold positions of 5,010,976 shares during the same period.